Immuron Clinical Trials Update

Highlights: US Naval Medical Research Command campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been...

Related Keywords

Australia ,Bayview ,Maryland ,United States ,Monash ,South Australia ,Baltimore ,Johns Hopkins University ,Melbourne ,Victoria ,Australian ,Mohamed Al Ibrahim ,Steven Lydeamore ,Kawsar Talaat ,Immuron Limited ,Monash University ,Animal Ethics Committee ,Drug Administration ,Us Naval Medical Research Command ,Vivopharm Global Preclinical Services ,Clinical Research Facility Inpatient Unit ,Nasdaq ,Immunization Research ,Medical Research Command ,Principal Investigator Dr Kawsar Talaat ,Inpatient Unit ,Medical Campus ,Investigational Medical Product ,Clostridioides Difficile ,Principal Investigator Dr Mohamed Al Ibrahim ,Markets ,